{
    "organizations": [],
    "uuid": "ae21dd82e1cd0dcba15a11ab5e197144afc832f4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-orion-updates-primary-completion-d/brief-orion-updates-primary-completion-date-of-phase-iii-to-september-2018-idUSFWN1RG04P",
    "ord_in_thread": 0,
    "title": "BRIEF-Orion Updates Primary Completion Date Of Phase III To September 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Orion Oyj:\n* STATUS UPDATE OF THE PHASE III ARAMIS CLINICAL TRIAL WITH DAROLUTAMIDE IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER\n* ESTIMATED PRIMARY COMPLETION DATE IS NOW UPDATED TO SEPTEMBER 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-03T15:36:00.000+03:00",
    "crawled": "2018-04-04T12:09:49.029+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "orion",
        "oyj",
        "status",
        "update",
        "phase",
        "iii",
        "aramis",
        "clinical",
        "trial",
        "darolutamide",
        "patient",
        "prostate",
        "cancer",
        "estimated",
        "primary",
        "completion",
        "date",
        "updated",
        "september",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}